Krystal Biotech, Inc. (KRYS)
NASDAQ:KRYS
Want to see KRYS full AI Analyst Report?
KRYS Stock Chart & Stats
$274.21
-$3.73(-2.33%)
At close: 4:00 PM EST
$274.21
-$3.73(-2.33%)
Day’s Range― - ―
52-Week Range$130.50 - $356.50
Previous CloseN/A
Volume44.50K
Average Volume (3M)313.74K
Market Cap
$10.26B
Enterprise Value$9.58B
Total Cash (Recent Filing)$823.40M
Total Debt (Recent Filing)$9.11M
Price to Earnings (P/E)45.3
Beta0.77
Next Earnings
Aug 10, 2026EPS Estimate
1.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.75
Shares Outstanding29,479,755
10 Day Avg. Volume374,629
30 Day Avg. Volume313,741
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)5.85
Price to Sales (P/S)18.34
P/FCF Ratio37.77
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue22.96
Enterprise Value/Gross Profit24.74
Enterprise Value/Ebitda47.74
Forecast
1Y Price Target
$340.50Price Target Upside24.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)7.75
Revenue Forecast (FY)$522.14M
Bulls Say, Bears Say
Bulls Say
High Profitability And Strong Cash GenerationKrystal has transitioned to durable cash generation and exceptional margins driven by VYJUVEK: very high gross margins and substantial free cash flow provide funding optionality for commercialization and pipeline advancement without near‑term financing, strengthening long‑term financial flexibility.
Conservative Balance Sheet With Minimal DebtExtremely low leverage and a large cash position reduce solvency risk and enable sustained investment in global launches and clinical programs. The equity‑funded asset base and liquidity provide resilience to execution hiccups and support multi‑year R&D and regulatory activities.
Commercial Traction And Expanding Patient AccessStrong uptake, growing prescriber base and meaningful international revenue show durable commercial execution for a novel gene therapy. Established payer approvals and expanding prescriber adoption reduce commercialization risk and underpin recurring treatment demand over coming quarters.
Bears Say
Quarterly Revenue Unpredictability From Insurance SwitchoversInsurance transitions and maintenance dosing patterns create lumpy realized revenue despite underlying demand. This structural cadence hampers predictable topline pacing, complicates resource planning, and can magnify perceived volatility across reporting periods for the commercial business.
European Reimbursement And Pricing UncertaintyPending pricing and reimbursement outcomes in key European markets materially affect patient access and revenue potential. Protracted negotiations or adverse pricing decisions would constrain international expansion and long‑term revenue scalability for this orphan gene therapy franchise.
Historical Earnings And Cash Volatility; Slowing Growth SignalWhile current profitability is strong, the firm's track record includes multi‑year losses and volatile cash flow. Slowing recent annual growth highlights execution risk; this shorter earnings history increases uncertainty about sustainability of margins and growth across economic or access stress scenarios.
Krystal Biotech News
KRYS FAQ
What was Krystal Biotech, Inc.’s price range in the past 12 months?
Krystal Biotech, Inc. lowest stock price was $130.50 and its highest was $356.50 in the past 12 months.
What is Krystal Biotech, Inc.’s market cap?
Krystal Biotech, Inc.’s market cap is $10.26B.
When is Krystal Biotech, Inc.’s upcoming earnings report date?
Krystal Biotech, Inc.’s upcoming earnings report date is Aug 10, 2026 which is in 50 days.
How were Krystal Biotech, Inc.’s earnings last quarter?
Krystal Biotech, Inc. released its earnings results on May 04, 2026. The company reported $1.83 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.34.
Is Krystal Biotech, Inc. overvalued?
According to Wall Street analysts Krystal Biotech, Inc.’s price is currently Undervalued.
Does Krystal Biotech, Inc. pay dividends?
Krystal Biotech, Inc. does not currently pay dividends.
What is Krystal Biotech, Inc.’s EPS estimate?
Krystal Biotech, Inc.’s EPS estimate is 1.77.
How many shares outstanding does Krystal Biotech, Inc. have?
Krystal Biotech, Inc. has 29,479,755 shares outstanding.
What happened to Krystal Biotech, Inc.’s price movement after its last earnings report?
Krystal Biotech, Inc. reported an EPS of $1.83 in its last earnings report, beating expectations of $1.49. Following the earnings report the stock price went up 7.86%.
Which hedge fund is a major shareholder of Krystal Biotech, Inc.?
Currently, no hedge funds are holding shares in KRYS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Krystal Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$340.50 (24.17% Upside)
$340.50 (24.17% Upside)
Blogger Sentiment
Bullish
KRYS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 74.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $15.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.8%
Last 30 Days ▲ 30.6%
Last 30 Days ▲ 30.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
163.50%
12-Months-Change
Fundamentals
Return on Equity
19.25%
Trailing 12-Months
Asset Growth
30.02%
Trailing 12-Months
Company Description
Krystal Biotech, Inc.
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
KRYS Company Deck
KRYS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial momentum, robust profitability, a growing international launch and a busy clinical pipeline with multiple near-term readouts and regulatory designations — balanced by operational challenges including insurance switchovers, start-stop treatment dynamics, rising G&A, certain program-specific regulatory/timing requirements, and ongoing European pricing negotiations. Overall the positives (revenue growth, high gross margin, strong cash position, multiple upcoming data readouts and regulatory designations) materially outweigh the operational and timing headwinds described.View all KRYS earnings summariesKRYS Stock 12 Month Forecast
Average Price Target
$340.50
▲(24.17% Upside)
Technical Analysis
Ownership Overview
11.14% Insiders
30.42% Mutual Funds
32.64% Other Institutional Investors
0.53% Public Companies and Individual Investors